Odyssey Therapeutics, Inc.
ODTX
$17.62
$0.301.73%
NASDAQ
| 12/31/2023 | |||||
|---|---|---|---|---|---|
| Net Income | -28.86M | ||||
| Total Depreciation and Amortization | 1.23M | ||||
| Total Amortization of Deferred Charges | -- | ||||
| Total Other Non-Cash Items | 2.01M | ||||
| Change in Net Operating Assets | -30.00K | ||||
| Cash from Operations | -25.65M | ||||
| Capital Expenditure | -2.87M | ||||
| Sale of Property, Plant, and Equipment | 0.00 | ||||
| Cash Acquisitions | -- | ||||
| Divestitures | -- | ||||
| Other Investing Activities | -75.69M | ||||
| Cash from Investing | -78.55M | ||||
| Total Debt Issued | -- | ||||
| Total Debt Repaid | 0.00 | ||||
| Issuance of Common Stock | 26.00K | ||||
| Repurchase of Common Stock | -- | ||||
| Issuance of Preferred Stock | 96.57M | ||||
| Repurchase of Preferred Stock | -- | ||||
| Total Dividends Paid | -- | ||||
| Other Financing Activities | -- | ||||
| Cash from Financing | 96.60M | ||||
| Foreign Exchange rate Adjustments | -33.00K | ||||
| Miscellaneous Cash Flow Adjustments | -- | ||||
| Net Change in Cash | -7.64M | ||||